Meeting Insights

Meeting Insights

First-Line Treatment for Advanced Renal Cell Carcinoma: Highlights From ASCO Genitourinary Cancers Symposium 2023

Kathryn E. Beckermann, MD, PhD, assistant professor of medicine and chief academic fellow in the Division of Hematology and Oncology at the Vanderbilt University School of Medicine in Nashville, provided insight into research on the first-line treatment of advanced RCC presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. READ MORE »

Subsequent-Line Treatment Options for Hepatocellular Carcinoma With Progression: ASCO 2023

Laura Goff, MD, hematologic oncologist, associate professor of medicine at Vanderbilt-Ingram Cancer Center (VICC), and executive medical director for the VICC Cancer Patient Care Center, shared her insights from this year’s ASCO Gastrointestinal Cancers Symposium. READ MORE »

Treatment Approaches for Advanced Hepatocellular Carcinoma: Observations From EMSO Congress 2022

Josep M Llovet, MD, PhD, FAASLD, shares his insights into HCC research presented at the 2022 European Society for Medical Oncology (ESMO) Congress. READ MORE »

Treatment Strategies for Advanced Renal Cell Carcinoma: Insights From 2022 IKCS: North America

Moshe C. Ornstein, MD, MA, shares his insights into aRCC research presented at 2022 IKCS: North America. READ MORE »

2022 ASCO® Annual Meeting: Updates on the Treatment of Advanced Renal Cell Carcinoma

David Braun, MD, PhD, shares his perspective on the clinical impact and importance of selected aRCC studies presented at ASCO. READ MORE »

Treatment Advances in Metastatic Breast Cancer: Highlights from ASCO® 2022

Adam M Brufsky, MD, PhD, FACP, is among the many clinician scientists who presented results of research on metastatic breast cancer. READ MORE »

Treatment Approaches for Renal Cell Carcinoma: Insight From the 2022 Genitourinary Cancers Symposium

Robert Dreicer, MD, discussed research on RCC presented at the meeting and highlighted key takeaways. READ MORE »

Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium

Muhammad Shaalan Beg, MD, the director for GI Medical Oncology at University of Texas Southwestern Medical Center in Dallas, shared insight and key takeaways from the latest advances in treatment approaches for advanced hepatocellular carcinoma (HCC) presented at the meeting. READ MORE »

ASH Conference 2021: Follicular Lymphoma Therapeutic Updates

Connie Lee Batlevi, MD, PhD, a medical oncologist and clinical researcher at Memorial Sloan Kettering Cancer Center in NYC, shared her insight on some of the presentations at the 2021 American Society of Hematology (ASH) Conference and what the research findings mean for clinical practice. READ MORE »

Advanced Kidney Cancer Research: Insights From IKCS 2021

Ulka Vaishampayan, MBBS, shared key takeaways from the research focused on advanced renal cell carcinoma (aRCC) presented at the meeting. Dr Vaishampayan is a professor of internal medicine/oncology and director of the Multitumor Experimental Therapeutics Team/Phase I program at the University of Michigan Rogel Cancer Center. READ MORE »

Cutting-Edge Advanced RCC Research Poised to Improve Patient Outcomes

Philippe Spiess, MD, genitourinary oncologist and assistant chief of Surgical Services at Moffitt Cancer Center, Tampa, Florida, shares his thoughts on this fascinating — and potentially game-changing — research. READ MORE »

Meeting Insights: Practice-Changing Presentations in Renal Cell Carcinoma: Insights From ASCO® 2021

In an interview with Cancer Therapy Advisor, Elizabeth Plimack, MD, discusses practice-changing research on renal cell carcinoma presented at the 2021 American Society of Clinical Oncology® (ASCO®) Annual Meeting. READ MORE »

Highlights on Renal Cell Carcinoma From the 2021 Genitourinary Cancers Symposium

In an interview with Cancer Therapy Advisor, Sumanta Pal, MD, clinical professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope in Duarte, California, discussed promising research with the potential to improve outcomes in kidney cancer. READ MORE »

Previewing Advances in the HCC Paradigm Through Insights From the 2021 Gastrointestinal Cancers Symposium

In an interview with Cancer Therapy Advisor, Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, discussed key insights in hepatocellular carcinoma (HCC) and their implications for a new year of advances in this disease setting. READ MORE »

Insights From the 62nd ASH Annual Meeting and Exposition

Laura Michaelis, MD, associate professor reviews impactful findings from the 62nd ASH Annual Meeting and Exposition. READ MORE »

Reflections on IKCS 2020: The Nuance of Treatment Selection in RCC

Dr McKay spoke to CTA following IKCS 2020 about identifying biomarkers, the international use of the novel immunotherapy combinations, the role of cytoreductive nephrectomy, and nuances around adjuvant therapy in RCC. READ MORE »

New in Renal Cell Carcinoma: Data From ESMO Virtual Congress 2020

Dr George discussed the results of CheckMate-9ER, the value of whole-genome sequencing, and the importance of the use of a biomarker-driven approach to select therapies for less-common histologies. READ MORE »

NSCLC: A Look at Top Abstracts From ESMO Virtual Congress 2020

Grace Dy, MD, dissects some of the top abstracts from ESMO Virtual Congress 2020 in the field of non-small cell lung cancer. READ MORE »

EHA25: Key Findings in Multiple Myeloma

Maximilian Merz, MD, outlines research from EHA25 that had practice-changing implications for the treatment of patients with multiple myeloma. READ MORE »

Acute Myeloid Leukemia Data From the ASCO20 Virtual Scientific Program

Dr Estey discusses some of the most compelling research in the field of AML presented during the ASCO20 Virtual Scientific Program. READ MORE »

Next Steps in Breast Cancer Treatment: Observations From the ASCO20 Virtual Scientific Program

Cancer Therapy Advisor connected with Adam M. Brufsky, MD, PhD, who offered his thoughts about ASCO20 and how new findings from breast cancer trials can be used in practice. READ MORE »

Insights From the ESMO Congress 2019: Immunotherapies in Lung Cancer

Cancer Therapy Advisor spoke to David Spigel, MD, to find out how knowing tumor mutational burden (TMB) values may not be as telling as previously suspected, how he predicts there will be a move toward blood-based testing as a more universal approach for the detection of oncologic driver mutations in lung cancer. READ MORE »

Using the Data From ESMO Congress 2019 in Practice: Breast Cancer

Cancer Therapy Advisor sat down with Leisha A. Emens, MD, PhD, to discuss when to add platinum-based chemotherapy to standard neoadjuvant chemotherapy in triple-negative breast cancer, the role of CDK 4/6 inhibitors in treatment, and more. READ MORE »

Insights From ESMO Congress 2019: Osimertinib in Non-Small Cell Lung Cancer

Cancer Therapy Advisor sat down with Roy S. Herbst, MD, PhD, to discuss the FLAURA trial, how gene sequencing is now the standard of care if osimertinib is to be considered as a treatment option, the use of ctDNA in lung cancer, and how there is an entire spectrum of resistance mutations that are now emerging as research progresses. READ MORE »